Topical Raplixa for Surgical Bleeding in Children

Inclusion Criteria

• •Was at least 36 weeks gestational age at birth (if an infant less than 6 months old) and is no older than 17 years at time of treatment
• •Has a legal representative (parent or guardian) who signed an institutional review board (IRB)-approved informed consent document
• •If at least 7 years old or appropriate age as defined by local regulations, may be required to sign an IRB-approved assent document
• •Is scheduled to undergo one of the surgical procedures described in the protocol
• •If female and of child-bearing potential, subject has negative pregnancy test on the day of surgery (baseline)
• •If a sexually active male or female of reproductive potential, agrees to use a medically accepted form of contraception from the time of consent to completion of all follow-up study visits
• •Has mild or moderate bleeding/oozing
• •Has TBS surface area no more than 100 cm\^2
• •Has not received any whole blood, fresh frozen plasma (FFP), cryoprecipitate, or platelets within 24 hours prior to study drug (packed red blood cell (PRBC) transfusions are allowed)
• •Had no complication during surgery other than bleeding which, in the opinion of the Investigator, may interfere with the assessment of efficacy or safety